| METHODS
This population-based cohort study utilized a combined Canada-US registry data set derived from the Canadian CF Registry (CCFR) and US CF Foundation Patient Registry (CFFPR). The process of harmonizing and combining the national data sets has been described in detail in a recent publication. 5 The combined data set encompasses 42
Canadian and over 110 US CF care centers from 1986 to 2013. The CCFR captures virtually all CF patients in Canada, 6 and the CFFPR captures approximately 94% of patients from accredited CF care centers in the United States. 7 For this study, patients who underwent their first lung transplant in each country from 1986 to 2013 were selected for analysis. Subjects with prior nonlung transplants (eg liver, kidney, and other) were excluded. The study was approved by the Ethics Review Boards of St. Michael's Hospital (Toronto, Ontario) and Seattle
Children's Hospital (Seattle, WA).
Demographic, clinical, and treatment variables collected in the year prior to lung transplant were analyzed as the exact date of transplant was missing for 52% of CFFPR cases. In the combined data set, these variables corresponded to the first visit of the year in both countries as the CCFR only reported first annual visit clinical measurements prior to 2012. There were 110 patients (2.7%) whose FEV 1 was above 53% predicted, the highest pretransplant FEV 1 documented in a prior analysis using the CCFR. 3 For these patients, the FEV 1% predicted was set to missing as they represented potential errors.
The GLI reference equations were used to calculate FEV 1% pre- Continuous variables were summarized using median and range.
Categorical variables were summarized as frequency and proportions.
Differences between the two countries were assessed using the Mann-Whitney-Wilcoxon test for continuous variables and the chisquare test for categorical variables. P-values are two-sided, and due to the large sample size, a standardized difference (SD) was also calculated. Tests were deemed statistically significant if the P-value was less than .001 and SD > 10. 8 All analyses were performed in R version 3.3.0.
| RESULTS
Between 1986 (Table 1) . However, the median age of transplant was lower in the United States compared to Canada, with a higher proportion undergoing a transplant at <18 years of age (13.8% vs 6.4%; SD 24.7)
although the difference has decreased since 2010 (8.8% vs 4.5%; SD 17.5).
There were higher rates of missing CF genotype information in (Table S1 ). The number of pediatric lung transplants performed in Canada was small which limits statistical comparisons of clinical characteristics between the two countries for this age group, but there were no obvious differences in this subgroup relative to the overall group comparison (Table S2) . As a result, the higher rates of pediatric CF transplants in the United States presumably reflect national differences in lung disease severity (and greater need for transplant) during the pediatric T A B L E 1 (Continued) years as opposed to being reflective of differences in transplant referral practices. 
| DISCUSSION

